Medical Oncology, Год журнала: 2023, Номер 40(11)
Опубликована: Окт. 19, 2023
Язык: Английский
Nature Reviews Clinical Oncology, Год журнала: 2024, Номер 21(4), С. 257 - 277
Опубликована: Фев. 7, 2024
Язык: Английский
Процитировано
102
Expert Review of Vaccines, Год журнала: 2024, Номер 23(1), С. 336 - 348
Опубликована: Фев. 19, 2024
Introduction The rapid development of mRNA vaccines against SARS-CoV-2 has revolutionized vaccinology, offering hope for swift responses to emerging infectious diseases. Initially met with skepticism, have proven effective and safe, reducing vaccine hesitancy amid the evolving COVID-19 pandemic. pandemic demonstrated that time required modify counter new mutant strains is significantly shorter than it takes pathogens mutate generate variants can thrive in vaccinated populations. This highlights notion technology appears be outpacing viruses ongoing evolutionary race.
Язык: Английский
Процитировано
8
American Society of Clinical Oncology Educational Book, Год журнала: 2024, Номер 44(3)
Опубликована: Апрель 26, 2024
The origins of cancer vaccines date back to the 1800s. Since then, there have been significant efforts generate against solid and hematologic malignancies using a variety platforms. To date, these generally met with minimal success. However, in era improved methods technological advancements, supported by compelling preclinical clinical data, wave renewed interest field offers promise discovering field-changing paradigms management established resected disease vaccines. These include novel approaches personalized neoantigen vaccine development, as well innovative immune-modulatory (IMVs) that facilitate activation antiregulatory T cells limit immunosuppression caused regulatory immune cells. This article will introduce some limitations affected development over past several decades, followed an introduction latest advancements IMV therapy, then conclude discussion newest technologies progress are occurring across space. Cancer among most promising frontiers for breakthrough innovations strategies poised make measurable impact ongoing fight cancer.
Язык: Английский
Процитировано
8
Journal of Biomedical Science, Год журнала: 2025, Номер 32(1)
Опубликована: Янв. 21, 2025
Abstract Nucleic acid vaccines have emerged as crucial advancements in vaccine technology, particularly highlighted by the global response to COVID-19 pandemic. The widespread administration of mRNA against billions globally marks a significant milestone. Furthermore, approval an for Respiratory Syncytial Virus (RSV) this year underscores versatility technology. In oncology, combination encoding neoantigens and immune checkpoint inhibitors (ICIs) has shown remarkable efficacy eliciting protective responses diseases like melanoma pancreatic cancer. Although use DNA been limited India, inherent stability at room temperature cost-effectiveness present viable option that could benefit developing countries. These advantages may help address some challenges associated with vaccines. Currently, several trials are exploring DNA-encoded ICIs across various cancer types. studies highlight promising role nucleic acid-based next generation immunotherapeutic agents treatment. This review will delve into recent current developmental status both DNA-based
Язык: Английский
Процитировано
1
Biomedicine & Pharmacotherapy, Год журнала: 2023, Номер 167, С. 115513 - 115513
Опубликована: Сен. 22, 2023
Immune effector cells in the microenvironment tend to be depleted or remodeled, unable perform normal functions, and even promote malignant characterization of tumors, resulting formation immunosuppressive microenvironments. The strategy reversing has been widely used enhance tumor immunotherapy effect. Signal transducer activator transcription 3 (STAT3) was found a crucial regulator activation as well factor, stimulating cell proliferation, survival, invasiveness metastasis. Therefore, regulating immune by targeting STAT3 oncogenic pathway might new cancer therapy strategy. This review discusses pleiotropic effects on populations that are critical for tumorigenesis, introduces novel strategies immunotherapy. Lastly, we summarize conventional drugs STAT3-targeting anti-tumor applications.
Язык: Английский
Процитировано
21
Biomolecules, Год журнала: 2024, Номер 14(4), С. 503 - 503
Опубликована: Апрель 21, 2024
Cancer remains one of the global leading causes death and various vaccines have been developed over years against it, including cell-based, nucleic acid-based, viral-based cancer vaccines. Although many effective in vivo clinical studies some FDA-approved, there are major limitations to overcome: (1) developing universal vaccine for a specific is difficult, as tumors with different antigens individuals, (2) tumor may be similar body’s own antigens, (3) possibility recurrence. Therefore, personalized ability distinguish between indispensable. This paper provides comprehensive review types highlights important factors necessary efficient Moreover, application other technologies therapy discussed. Finally, several insights conclusions presented, such using cold plasma stem cells future vaccines, tackle developmental process.
Язык: Английский
Процитировано
7
Molecular Aspects of Medicine, Год журнала: 2024, Номер 101, С. 101324 - 101324
Опубликована: Дек. 3, 2024
This review provides a comprehensive overview of the evolving landscape cancer vaccines, highlighting their potential to revolutionize tumor prevention. Building on success vaccines against virus-related cancers, such as HPV- and HBV-associated cervical liver current challenge is extend these achievements prevention non-viral tumors treatment preneoplastic or early neoplastic lesions. analyzes critical aspects preventive anti-cancer vaccination, focusing choice target antigens, development effective vaccine platforms technologies, use various model systems for preclinical testing, from laboratory rodents companion animals.
Язык: Английский
Процитировано
6
Cancer Biology and Medicine, Год журнала: 2024, Номер unknown, С. 1 - 15
Опубликована: Авг. 22, 2024
Colorectal cancer (CRC) is the third most common and second leading cause of cancer-related deaths worldwide. Dendritic cells (DCs) constitute a heterogeneous group antigen-presenting that are important for initiating regulating both innate adaptive immune responses. As crucial component system, DCs have pivotal role in pathogenesis clinical treatment CRC. cross-present tumor-related antigens to activate T trigger an antitumor response. However, function impaired tolerance promoted due presence tumor microenvironment. This review systematically elucidates specific characteristics functions different DC subsets, as well play response within CRC Moreover, how contribute progression potential therapies enhance immunity on basis existing data also discussed, which will provide new perspectives approaches immunotherapy patients with
Язык: Английский
Процитировано
5
Vaccines, Год журнала: 2023, Номер 11(12), С. 1783 - 1783
Опубликована: Ноя. 29, 2023
Therapeutic vaccines are a promising alternative for active immunotherapy different types of cancers. cancer aim to prevent immune system responses that not targeted at the tumors only, but also boost anti-tumor immunity and promote regression or eradication malignancy without, with minimal, adverse events. Clinical trial data have pushed development forward, US Food Drug Administration authorized first therapeutic vaccine. In present review, we discuss various approaches vaccines, along current state knowledge future prospects. We how tumor-induced suppression limits effectiveness vaccinations, strategies overcome this barrier design efficacious, long-lasting in generation vaccines.
Язык: Английский
Процитировано
12
Drug Discovery Today, Год журнала: 2024, Номер unknown, С. 104188 - 104188
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
4